Latham & Watkins Advises Jade Biosciences on US$45 Million Private Placement

Jade Biosciences, Inc., (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, has announced that it has entered into a securities purchase agreement with BB Biotech for a private placement financing that is expected to result in gross proceeds of approximately US$45 million to the company, before offering expenses.

Latham & Watkins LLP is advising Jade Biosciences in the private placement financing with a corporate team led by San Diego partners Cheston Larson and Matt Bush, and counsel Anthony Gostanian, with assistance from Katie Raya.